Clobetasol propionate is a Small Molecule owned by GSK, and is involved in 9 clinical trials, which were completed.
Clobetasol Propionate is a synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.
The revenue for Clobetasol propionate is expected to reach a total of $3.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Clobetasol propionate NPV Report.
Clobetasol propionate is currently owned by GSK.
Clobetasol propionate Overview
Clobetasol Propionate (Dermovate, Dermoval, Clobesol, Tenovate, Psorex, Dermoxin, Dermoxinale and Olux-E) is a derivative of prednisolone with high glucocorticoid activity acts as an corticosteriod agent. It is formulated as cream, ointment, aerosol foam and solution for topical route and cutaneous route of application. Clobetasol Propionate is indicated for the treatment of resistant dermatoses such as psoriasis (excluding widespread plaque psoriasis), recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other skin conditions which do not respond satisfactorily to less active steroids; psoriasis and recalcitrant eczemas of the scalp.
GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020.
The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.
Quick View – Clobetasol propionate
|Highest Development Stage
#Revenue #Clobetasol #propionate #expected #CAGR